Liquid Glucagon: Improving Utilisation for Emergency Treatment of Severe Hypoglycemia

Arecor是开发稳定制剂的全球领导者，拥有针对糖尿病差异化产品概念的内部开发计划。Arecor有坚实的计划，将这些产品概念开发到I期临床概念验证和随后的资产许可。其中一个产品概念是液体胰高血糖素，既用于紧急使用，也作为双激素泵的关键组成部分。Arecor已经开发出胰高血糖素的原型液体配方，显示出足够的稳定性，可以作为可行的商业产品。在InnovateUK的关键支持下，Arecor正在通过进一步优化以确保与选定的输送设备的兼容性、毒理学研究、正式稳定性研究和验证的药代动力学研究，推进该资产的临床前开发。在这项研究之后，Arecor将准备进入I期人体试验。稳定的液体胰高血糖素产品将改变胰高血糖素用于严重低血糖发作紧急治疗的方式，消除了对目前已上市的冻干产品进行复杂重组的需要。此外，对于液体胰高血糖素作为双激素泵的关键成分的公认需求也将由本产品解决。

Arecor is a world leader in developing stable formulations of therapeutics, with in-house development programmes aimed at differentiated product concepts in diabetes. Arecor has solid plans for developing those product concepts to Phase I clinical proof-of-concept and subsequent licensing of the assets. One of the product concepts is liquid glucagon, both for emergency use and as a critical component for a bihormonal pump. Arecor has developed prototype liquid formulations of glucagon showing sufficient stability for a viable commercial product. With the critical support from InnovateUK, Arecor is progressing this asset through pre-clinical development by performing further optimisation to ensure compatibility with a selected delivery device, toxicology studies, formal stability studies and validated pharmacokinetic studies. Following this study, Arecor will be ready to move into Phase I human trial. Stable liquid glucagon product will transform the way glucagon is used for emergency treatment of severe hypoglycaemia episodes by removing the need for a complex reconstitution of the currently marketed lyophilised products. In addition, there is a recognised need for liquid glucagon as a critical component of bihormonal pumps that will also be addressed by this product.